Retraction: The RAF inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells (Cancer Research (2006) 66 (1611–1619) DOI: 10.1158/0008-5472.CAN-05-0808);The raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1611-1619

  Panka, David J ^a   Wang, Wei ^b   Atkins, Michael B ^a   Mier, James W ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENOSINE DIPHOSPHATE RIBOSE; APOPTOSIS INDUCING FACTOR; CASPASE; CASPASE INHIBITOR; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; SORAFENIB;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION;

EID: 32944479041     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-19-2621     Document Type: Erratum

References (42)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-7.
3. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
4. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-5.
5. Rajagopalan H, Bardelli A, Langauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
6. V599E in human melanoma abrogates transformation. Cancer Res 2003;64:5198-202.
7. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
8. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
9. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
10. Alsina J, Gorsk DH, Germino FJ, et al. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003;9:6419-25.
11. U. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff A-K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64:5186-92.
12. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998;92:253-63.
13. Lo TL, Yusoff P, Fong CW, et al. The Ras/Mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Res 2004;64:6127-36.
14. Sasaki A, Taketomi T, Kato R, et al. Mammalian Sprouty 4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol 2003;5:427-32.
15. Tsavachidou D, Coleman ML, Athanasiadis G, et al. SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild type BRAF but not with the V599E mutant. Cancer Res 2004;64:5556-9.
16. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo H-M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein Bad. Cancer Res 2003;63:8330-7.
17. L. Cell 1996;87:619-28.
18. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003;39:615-47.
19. Kaufmann T, Schinzel A, Borner C. Bcl-w(edding) with mitochondria Trends Cell Biol 2004;14:8-12.
20. Schinzel A, Kaufmann T, Schuler M, et al. Conformational control of Bax localization and apoptotic activity by Pro168. J Cell Biol 2004;164:1021-32.
21. Cartron PF, Gallenne T, Bougras G, et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA Mol Cell 2004;16:807-18.
22. Yin X-M, Oltvai ZN, Korsemeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
23. Erhardt P, Schremser EJ, Cooper GM. B-raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-15.
24. Huser M, Luckett J, Chiloeches A, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001;20:1940-51.
25. Hindley A, Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 2002;115:1575-81.
26. Yamaguchi O, Watanabe T, Nishida K, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004;114:937-43.
27. O'Neill E, Rushworth L, Baccarini M, Kolch W. Role of the kinase MST2 in suppression of apoptosis by the protooncogene product Raf-1. Science 2004;306:2267-70.
28. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-73.
29. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
30. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
31. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
32. Lomax MI, Hewett-Emmett D, Yang TL, Grossman LI. Rapid evolution of the human gene for cytochrome c oxidase subunit IV. Proc Natl Acad Sci U S A 1992;89:5266-70.
33. Nevins JR. Isolation and analysis of nuclear RNA. Methods Enzymol, Academic Press 1987;152:234-6.
34. Dixelius J, Cross M, Matsumoto T, et al. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2000;62:6723-9.
35. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999;144:903-14.
36. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 2001;276:45193-200.
37. Daugas E, Nochy D, Ravagnan L, et al. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 2000;476:118-23.
38. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147-50.
39. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004;23:2785-96.
40. Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002;419:367-74.
41. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
42. Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002;115:4727-34.